Would you offer other antibody-drug conjugates to a patient who had a history of G2 trastuzumab deruxtecan-induced pneumonitis that is now resolved?
This includes TDM-1, datopotamab deruxtecan, and sacituzumab govitecan
Community PollStarted
Would you offer TDM-1 to a patient who had a history of G2 Enhertu-induced pneumonitis that is now resolved?
89 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on
There are no prospective data to guide this decision; the decision requires careful individualization. TDM-1 (ado-trastuzumab emtansine has a substantially lower pneumonitis risk than trastuzumab deruxtecan (1.6-1.9% with TDM-1 compared to 9.6-10.5% with trastuzumab deruxtecan), and TDM-1 uses a dif...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Warren Alpert Medical School of Brown University
Answered on
We aren't seeing a significant incidence of ILD with the other ADCs, so, yes, I would, but would probably avoid datapotamab deruxtecan, given the identical "payload" for that agent as with T-Dxd. Would be comfortable with T-DM1 in a HER2+ patient, or sacituzumab govitecan in a HER2- patient (whether...
Join for free or sign in to see the full answer